{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:37:20Z","timestamp":1781548640521,"version":"3.54.5"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":177,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>COVID-19 has demonstrated the power of RNA vaccines as part of a pandemic response toolkit. Another virus with pandemic potential is influenza. Further development of RNA vaccines in advance of a future influenza pandemic will save time and lives. As RNA vaccines require formulation to enter cells and induce antigen expression, the aim of this study was to investigate the impact of a recently developed bioreducible cationic polymer, pABOL for the delivery of a self-amplifying RNA (saRNA) vaccine for seasonal influenza virus in mice and ferrets. Mice and ferrets were immunized with pABOL formulated saRNA vaccines expressing either haemagglutinin (HA) from H1N1 or H3N2 influenza virus in a prime boost regime. Antibody responses, both binding and functional were measured in serum after immunization. Animals were then challenged with a matched influenza virus either directly by intranasal inoculation or in a contact transmission model. While highly immunogenic in mice, pABOL-formulated saRNA led to variable responses in ferrets. Animals that responded to the vaccine with higher levels of influenza virus-specific neutralizing antibodies were more protected against influenza virus infection. pABOL-formulated saRNA is immunogenic in ferrets, but further optimization of RNA vaccine formulation and constructs is required to increase the quality and quantity of the antibody response to the vaccine.<\/jats:p>","DOI":"10.1093\/oxfimm\/iqac004","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:41:27Z","timestamp":1656333687000},"source":"Crossref","is-referenced-by-count":12,"title":["Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets"],"prefix":"10.1093","volume":"3","author":[{"given":"P F","family":"McKay","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-623X","authenticated-orcid":false,"given":"R","family":"Frise","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Blakney","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R","family":"Bouton","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Samnuan","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kugathasan","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yeow","sequence":"additional","affiliation":[{"name":"Departments of Materials and Bioengineering, Institute of Biomedical Engineering, Imperial College London , London SW7 2AZ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Stevens","sequence":"additional","affiliation":[{"name":"Departments of Materials and Bioengineering, Institute of Biomedical Engineering, Imperial College London , London SW7 2AZ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W S","family":"Barclay","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-8741","authenticated-orcid":false,"given":"J S","family":"Tregoning","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Shattock","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London , London W2 1PG,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2024112016142210600_iqac004-B1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cei.13517","article-title":"Vaccines for COVID-19","volume":"202","author":"Tregoning","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2024112016142210600_iqac004-B2","article-title":"An update on self-amplifying mrna vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel"},{"key":"2024112016142210600_iqac004-B3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"2024112016142210600_iqac004-B4","author":"Pollock","year":"2021"},{"key":"2024112016142210600_iqac004-B5","first-page":"1","volume-title":"Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action","author":"Maruggi"},{"key":"2024112016142210600_iqac004-B6","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acsnano.0c00326","article-title":"Big is beautiful: Enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer","volume":"14","author":"Blakney","year":"2020","journal-title":"ACS Nano"},{"key":"2024112016142210600_iqac004-B7","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1016\/j.vaccine.2021.08.010","article-title":"A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future","volume":"39","author":"Moore","year":"2021","journal-title":"Vaccine"},{"key":"2024112016142210600_iqac004-B8","doi-asserted-by":"crossref","first-page":"020421","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR project","volume":"9","author":"Paget","year":"2019","journal-title":"J Glob Health"},{"key":"2024112016142210600_iqac004-B9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3201\/eid2406.172114","article-title":"Ferrets as models for influenza virus transmission studies and pandemic risk assessments","volume":"24","author":"Belser","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2024112016142210600_iqac004-B10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Therapy"},{"key":"2024112016142210600_iqac004-B11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2024112016142210600_iqac004-B12","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat Commun"},{"key":"2024112016142210600_iqac004-B13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J Virol"},{"key":"2024112016142210600_iqac004-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur J Immunol"},{"key":"2024112016142210600_iqac004-B15","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat Commun"},{"key":"2024112016142210600_iqac004-B16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J Control Release"},{"key":"2024112016142210600_iqac004-B17","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1128\/JVI.03159-15","article-title":"Use of the microparticle NanoSiO2 as an adjuvant to boost vaccine immune responses in neonatal mice against influenza","volume":"90","author":"Russell","year":"2016","journal-title":"J Virol"},{"key":"2024112016142210600_iqac004-B18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00321","article-title":"DNA vaccines encoding antigen targeted to MHC class II induce influenza-specific CD8+ T cell responses, enabling faster resolution of influenza disease","volume":"7","author":"Lambert","year":"2016","journal-title":"Front Immunol"},{"key":"2024112016142210600_iqac004-B19","doi-asserted-by":"crossref","first-page":"e1008395","DOI":"10.1371\/journal.ppat.1008395","article-title":"Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog"},{"key":"2024112016142210600_iqac004-B20","doi-asserted-by":"crossref","first-page":"e43303","DOI":"10.1371\/journal.pone.0043303","article-title":"Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model","volume":"7","author":"Roberts","year":"2012","journal-title":"PLoS ONE"},{"key":"2024112016142210600_iqac004-B21"},{"key":"2024112016142210600_iqac004-B22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.32614\/RJ-2016-060","article-title":"ggfortify: unified interface to visualize statistical result of popular R packages","volume":"8","author":"Tang","year":"2016","journal-title":"R Journal"},{"key":"2024112016142210600_iqac004-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v008.i11","article-title":"Scatterplot3d\u2014an R package for visualizing multivariate data","volume":"8","author":"Ligges","year":"2003","journal-title":"J Statist Softw"},{"key":"2024112016142210600_iqac004-B24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/intimm\/dxu055","article-title":"Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens","volume":"26","author":"Sheppard","year":"2014","journal-title":"Int Immunol"},{"key":"2024112016142210600_iqac004-B25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00126","article-title":"Mouse models of influenza infection with circulating strains to test seasonal vaccine efficacy","volume":"9","author":"Groves","year":"2018","journal-title":"Front Immunol"},{"key":"2024112016142210600_iqac004-B26","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg"},{"key":"2024112016142210600_iqac004-B27","doi-asserted-by":"crossref","first-page":"113900","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2024112016142210600_iqac004-B28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","article-title":"Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA","volume":"29","author":"Blakney","year":"2021","journal-title":"Mol Ther"},{"key":"2024112016142210600_iqac004-B29","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1084\/jem.20181899","article-title":"TLR8: No gain, no pain","volume":"215","author":"Barrat","year":"2018","journal-title":"J Exp Med"},{"key":"2024112016142210600_iqac004-B30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molimm.2009.11.003","article-title":"A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition","volume":"47","author":"Liu","year":"2010","journal-title":"Mol Immunol"},{"key":"2024112016142210600_iqac004-B31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vetimm.2014.11.013","article-title":"Isolation, characterization, and functional analysis of ferret lymphatic endothelial cells","volume":"163","author":"Berendam","year":"2015","journal-title":"Vet Immunol Immunopathol"},{"key":"2024112016142210600_iqac004-B32","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1016\/j.vaccine.2022.03.064","article-title":"A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model","volume":"40","author":"Frise","year":"2022","journal-title":"Vaccine"},{"key":"2024112016142210600_iqac004-B33","doi-asserted-by":"crossref","first-page":"eaaw4361","DOI":"10.1126\/science.aaw4361","article-title":". Laboratory mice born to wild mice have natural microbiota and model human immune responses","volume":"365","author":"Rosshart","year":"2019","journal-title":"Science"},{"key":"2024112016142210600_iqac004-B34","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.10.001","article-title":"Mice with diverse microbial exposure histories as a model for preclinical vaccine testing","author":"Fiege","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2024112016142210600_iqac004-B35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-017-0036-2","article-title":"Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines","volume":"2","author":"Sutton","year":"2017","journal-title":"NPJ Vaccines"},{"key":"2024112016142210600_iqac004-B36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.vaccine.2018.02.061","article-title":"H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets","volume":"36","author":"Czak\u00f3","year":"2018","journal-title":"Vaccine"},{"key":"2024112016142210600_iqac004-B37","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3389\/fimmu.2017.01928","article-title":"Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant","volume":"8","author":"Christensen","year":"2017","journal-title":"Front Immunol"},{"key":"2024112016142210600_iqac004-B38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fimmu.2020.00135","article-title":"Natural killer cells dampen the pathogenic features of recall responses to influenza infection","volume":"11","author":"Mooney","year":"2020","journal-title":"Front Immunol"},{"key":"2024112016142210600_iqac004-B39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chom.2021.11.006","article-title":"Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates","volume":"30","author":"Zohar","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2024112016142210600_iqac004-B40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"2024112016142210600_iqac004-B41","author":"Singanayagam"},{"key":"2024112016142210600_iqac004-B42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2024112016142210600_iqac004-B43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2024112016142210600_iqac004-B44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024112016142210600_iqac004-B45","first-page":"369","article-title":"Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein","volume":"24","author":"Davies","year":"2021","journal-title":"Mol Therapy"}],"container-title":["Oxford Open Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ooim\/advance-article-pdf\/doi\/10.1093\/oxfimm\/iqac004\/44264262\/iqac004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ooim\/article-pdf\/3\/1\/iqac004\/60766853\/iqac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ooim\/article-pdf\/3\/1\/iqac004\/60766853\/iqac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T16:14:44Z","timestamp":1732119284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ooim\/article\/doi\/10.1093\/oxfimm\/iqac004\/6618536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oxfimm\/iqac004","relation":{},"ISSN":["2633-6960"],"issn-type":[{"value":"2633-6960","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"iqac004"}}